In last trading session, Nurix Therapeutics Inc (NASDAQ:NRIX) saw 0.44 million shares changing hands with its beta currently measuring 2.11. Company’s recent per share price level of $9.56 trading at $0.1 or 1.06% at ring of the bell on the day assigns it a market valuation of $728.81M. That closing price of NRIX’s stock is at a discount of -209.21% from its 52-week high price of $29.56 and is indicating a premium of 14.44% from its 52-week low price of $8.18. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.7 million shares which gives us an average trading volume of 983.52K if we extend that period to 3-months.

For Nurix Therapeutics Inc (NRIX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.33. Splitting up the data highlights that, out of 16 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 13 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.74 in the current quarter.

Nurix Therapeutics Inc (NASDAQ:NRIX) trade information

Upright in the green during last session for gaining 1.06%, in the last five days NRIX remained trading in the green while hitting it’s week-highest on Monday, 05/12/25 when the stock touched $9.56 price level, adding 7.9% to its value on the day. Nurix Therapeutics Inc’s shares saw a change of -49.26% in year-to-date performance and have moved 0.63% in past 5-day. Nurix Therapeutics Inc (NASDAQ:NRIX) showed a performance of -2.45% in past 30-days. Number of shares sold short was 13.69 million shares which calculate 10.95 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 17 to the stock, which implies a rise of 43.76% to its current value. Analysts have been projecting 16 as a low price target for the stock while placing it at a high target of 35. It follows that stock’s current price would drop -67.36% in reaching the projected high whereas dropping to the targeted low would mean a loss of -67.36% for stock’s current value.

Nurix Therapeutics Inc (NRIX) estimates and forecasts

This year revenue growth is estimated to rise 15.72% from the last financial year’s standing.

16 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 16.26M for the same. And 16 analysts are in estimates of company making revenue of 14.41M in the next quarter. Company posted 12.09M and 12.59M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -38.86% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -2.87% while estimates for its earnings growth in next 5 years are of -0.95%.

Nurix Therapeutics Inc (NASDAQ:NRIX)’s Major holders

Insiders are in possession of 1.41% of company’s total shares while institution are holding 112.51 percent of that, with stock having share float percentage of 114.12%. Investors also watch the number of corporate investors in a company very closely, which is 112.51% institutions for Nurix Therapeutics Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at NRIX for having 6.82 million shares of worth $142.33 million. And as of 2024-06-30, it was holding 10.9334 of the company’s outstanding shares.

The second largest institutional holder is REDMILE GROUP, LLC, which was holding about 4.42 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.0917 of outstanding shares, having a total worth of $92.32 million.

On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 2.29 shares of worth $21.86 million or 3.00% of the total outstanding shares. The later fund manager was in possession of 1.97 shares on Mar 31, 2025 , making its stake of worth around $18.85 million in the company or a holder of 2.59% of company’s stock.